SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple is currently trending as the token hovers near the psychological $1.00 level, fueling intense debate between long-term holders awaiting the Clarity Act and skeptics who view the asset as a stagnant project. Community sentiment is deeply polarized, with many retail investors expressing frustration over recent price stagnation and dilution concerns, while a vocal group of bulls remains committed, viewing the current price action as a strategic accumulation phase before potential regulatory breakthroughs.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors focus on the company's strategic pivot toward AI infrastructure following its acquisition of Northern Data, a move that has significantly expanded its GPU capacity and data center footprint. The community is actively debating the potential for a massive short squeeze due to high short interest, while simultaneously analyzing upcoming earnings and formal guidance as key catalysts for a long-term re-rating.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is seeing intense trading volume and volatility as investors react to a significant contract announcement with Anthropic and speculate on potential future data center tenant deals. The community remains deeply divided, with many traders debating whether the stock is a long-term infrastructure play or a target for algorithmic manipulation and frequent share dilution.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors digest a $200 million equity offering priced at $18.50, which is being viewed by many as a strategic move to fund massive expansion into AI-driven data center power infrastructure. The community is actively debating whether the dilution will create a long-term entry point or if the stocks rapid year-to-date climb has priced in the current project backlog.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the focus of intense debate as investors weigh record revenue and a massive backlog against an earnings miss and uncertainty regarding the Neutron launch timeline. The community remains deeply divided, with bulls pointing to the company's long-term strategic vision and new product announcements, while bears focus on the gap between current valuation and profitability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently facing significant market volatility as investors await phase 3 IZAR-1 trial data, with community sentiment split between frustration over delayed timelines and conviction in the company's long-term pipeline potential. Recent discussion is heavily centered on the upcoming mandatory earnings filing, which many expect to serve as a catalyst for either a major technical re-rate or further uncertainty regarding the drug's best-in-class positioning.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding (ONON) is facing sharp volatility following a surprise leadership shift as co-founders David Allemann and Caspar Coppetti return as co-CEOs, sparking community debate over the stability of the company's direction. While some investors remain bullish on the brand's premium positioning and innovation pipeline, others are reacting to the uncertainty by liquidating positions or betting on further downside as the stock tests key support levels.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending following a major strategic deal to acquire Boeings Wisk Aero, SkyGrid, and Insitu subsidiaries, which includes Boeing taking a significant equity stake in the company. The community is actively debating the implications of this expansion into defense and autonomous technology, with bulls highlighting the acquisition of profitable revenue streams and long-term partnerships, while bears remain focused on potential dilution and the company's path to certification.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd is currently drawing investor attention as it tests key technical support levels, with bulls highlighting the stock's potential for a valuation re-rating driven by strong growth in its e-commerce and fintech segments. Market participants are actively debating the impact of recent insider selling against the long-term potential of the company's ecosystem expansion and improving unit economics.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is experiencing high trading volume and significant price volatility as investors react to positive Phase 3 results for its lead depression treatment, DT120 ODT. While the community is actively debating the company's valuation, upcoming trial readouts for generalized anxiety disorder, and potential long-term commercialization strategies, many remain focused on whether the stock can maintain its momentum leading into these next catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade

The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MNPR Stock Rallies After Hours As Experimental Drug Shows Rapid Copper Balance Improvement In Genetic Disorder 

Equity

The open-label trial showed the drug helped the body remove excess copper more effectively and quickly, mainly by increasing copper excretion through stool.

Monopar Therapeutics (MNPR) Expected to Announce Earnings on Tuesday

Monopar Therapeutics (NASDAQ:MNPR) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-monopar-therapeutics-inc-stock...

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have earned a consensus recommendation of "Buy" from the thirteen research firms that are presently covering the stock, MarketBeat...

Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded Monopar Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday...

Brookline Capital Markets Forecasts MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets increased their Q1 2026 EPS estimates for Monopar Therapeutics in a research report...

HC Wainwright Brokers Reduce Earnings Estimates for MNPR

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2026 EPS estimates for Monopar Therapeutics in a report issued on Monday, March 30th. HC...

Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)

Chardan Capital reaffirmed a "buy" rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday...

Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) announced its earnings results on Friday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has been given a consensus rating of "Buy" by the thirteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and two have is...

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Monopar Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$113.59
Prev Close	$116.35
Open	$115.30
Dividend Yield	0.00%
50-Day Moving Average	$91.14
Beta	1.48
Avg. Volume	276,720.08
PE Ratio	-56.31

52-Week High	$124.82
52-Week Low	$29.18
Market Capitalization	$779.44M
EPS (Annual)	-$1.85
Price to Book	5.76
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info